No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 633 | 3,231 | 4,537 | 3,953 | 2,974 | 3,927 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | -67 | 24 | 157 | 39 | 26 | 65 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Lykis Limited engages in the fast moving consumer goods (FMCG) business in India and internationally. The company provides baby deos, body scrubs, baby ranges, biscuits, jellies, body lotions, roll-ons, shampoos, peel-off masks, perfumes, body mists, body creams, pharmas, soaps, charcoal ranges, hair colors, creams, toothpastes, lotions, body oils, biscuits and cookies, liquors, deos, coffees, confectioneries, hot pots, foods, stationary, and beverages. It also offers raw materials, such as Cocoa Butter Refined, Hard Paraffin Wax, Calcium Carbonate, Raw Talc, Extra Neutral Alcohol, Almond Oil, Cetostearyl Alcohol, Glycerin, Cetyl Alcohol, Hydroquinone, Pine Oil, D-Panthenol, light liquid paraffin, as well as food products. In addition, it sells pharma products, as well as commodities. It sells its products under the Lykis, H&H, Rox, Bonita, Monami, Special, Lykon, Bentol, Stylo, Bon Fami, Lyfresh, Calmon, Bon Dejeuner, Mellar, Bom Dia, Blue Fins, Bon Appetit, Senhorita, Polo Star, Leopard, Elephant, Carnoba, Classic, Maria, Spectra, Flite, Bahamas, Sparx, Metro, Cipro, Para, Dextrose and Water for Injection, Davigra, Dermogerme, A-DEM, Candicyl, Rectostop-HC, Nystatine, and Davimov brand names. The company was formerly known as Greenline Tea & Exports Limited and changed its name to Lykis Limited in July 2012. Lykis Limited was incorporated in 1984 and is headquartered in Mumbai, India.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lykis Limited (LYKISLTD.BO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Lykis Limited engages in the fast moving consumer goods (FMCG) business in India and internationally. The company provides baby deos, body scrubs, baby ranges, biscuits, jellies, body lotions, roll-ons, shampoos, peel-off masks, perfumes, body mists, body creams, pharmas, soaps, charcoal ranges, hair colors, creams, toothpastes, lotions, body oils, biscuits and cookies, liquors, deos, coffees, confectioneries, hot pots, foods, stationary, and beverages. It also offers raw materials, such as Cocoa Butter Refined, Hard Paraffin Wax, Calcium Carbonate, Raw Talc, Extra Neutral Alcohol, Almond Oil, Cetostearyl Alcohol, Glycerin, Cetyl Alcohol, Hydroquinone, Pine Oil, D-Panthenol, light liquid paraffin, as well as food products. In addition, it sells pharma products, as well as commodities. It sells its products under the Lykis, H&H, Rox, Bonita, Monami, Special, Lykon, Bentol, Stylo, Bon Fami, Lyfresh, Calmon, Bon Dejeuner, Mellar, Bom Dia, Blue Fins, Bon Appetit, Senhorita, Polo Star, Leopard, Elephant, Carnoba, Classic, Maria, Spectra, Flite, Bahamas, Sparx, Metro, Cipro, Para, Dextrose and Water for Injection, Davigra, Dermogerme, A-DEM, Candicyl, Rectostop-HC, Nystatine, and Davimov brand names. The company was formerly known as Greenline Tea & Exports Limited and changed its name to Lykis Limited in July 2012. Lykis Limited was incorporated in 1984 and is headquartered in Mumbai, India.